New in MDS
Here you will find articles that discuss the latest advances in MDS. You will be kept up to date on the newest FDA drug approvals for MDS drugs and treatment combinations. You will also learn about newly published research studies and any advances or findings that may contribute to your MDS treatment. We will discuss topics such as newly discovered MDS genetic mutations, exciting advances on new therapies like CAR-T therapy and NK cells, and improvements in allogeneic stem cell transplant.
Articles posted here will also aim to help answer common questions like "how is MDS treated?", "how is MDS diagnosed?", and "what causes MDS?".
With new MDS research being published almost every day, there is a lot to keep track of. The articles in this category will help you stay informed of new MDS treatment options and MDS research findings which will ultimately make you an empowered patient. Being empowered allows you to take important information to your healthcare team for discussion that will further enhance and personalize your care.
mds, aml, Bemcentinib, new in mds, life with mds, new treatment for HR-MDS
Ivosidenib and MDS. IDH1 mutation, relapsed or refractory MDS, Life with MDS, New in MDS
Imetelstat and low risk mds, life with mds, mds clinical trial, imetelstat and transfusions, transfusion independence
Immunosuppressive therapy can be an option for patients with lower-risk MDS (LR-MDS). A common type of immunotherapy for MDS is antithymocyte globulin (ATG).
Reblozyl, a first-in-class erythroid maturation agent, has been approved to treat MDS related anemia in ESA-naive patients with LR-MDS.
Sabatolimab binds to the surface of T-cells, releasing the breaks that the tumor applied to the immune system.
For more than 30 years, umbilical cord blood (UCB) has been an important stem cell source for patients with leukemia, lymphoma and MDS
Dr. Sekeres shared with us what he and his MDS colleagues are focusing their research on right now.